India Ranbaxy gets FDA nod for cyclobenzaprine HCL
MUMBAI, May 15 (Reuters) - Indian drugmaker Ranbaxy Laboratories Ltd (RANB.BO: Quote, Profile, Research) has received approval from the U.S. Food and Drug Administration for muscle relaxant cyclobenzaprine hydrochloride tablets, the regulator's website showed.
The FDA has also granted tentative approval to Lupin Pharmaceuticals Inc, a unit of Lupin Ltd (LUPN.BO: Quote, Profile, Research), for ramipril capsules, used in treating cardiovascular disease and high blood pressure. (Reporting by Rina Chandran; Editing by John Mair)
© Thomson Reuters 2009 All rights reserved
UK joins G20 push for world levy on banks
Britain threw its weight behind proposals to impose a global levy on banks to fund future bailouts and called on the G20 to work toward a $100 billion deal to meet the cost of climate change. Full Article | Full Coverage
Galleon case
U.S. insider trading probe widens
Fourteen people were charged with fraud and conspiracy in a dramatic widening of an insider trading scandal. Full Article
India
US
UK
